oral semaglutide vs injection for weight loss Choosing vs. Injectable FDA Approves Oral Semaglutide: First

SGLT2 inhibitors, such as empagliflozin and canagliflozin, have similar A1C-lowering properties (0.5%-0.8%) and out-of-pocket costs (except for alogliptin, which is available generically), but have the added advantages of CV risk reduction, BP-lowering, and weight loss

All patients had MRIs to check for brain volumes and PET scans to monitor glucose metabolism

Its recommended to avoid sun exposure, sweating, and applying makeup after the procedure

It is typically more suitable for lighter skin types and requires proper assessment to determine appropriateness

The safety review concludes that semaglutide typically induces mild-to-moderate and transient gastrointestinal disturbances and increases the risk of biliary disease, specifically cholelithiasis